Literature DB >> 22664114

Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.

Laila M Sherief1, Ahmad G Kamal, E A Khalek, Naglaa M Kamal, Attia A A Soliman, Asmaa M Esh.   

Abstract

BACKGROUND: The main strategy for minimizing anthracycline cardiotoxicity is early detection of high-risk patients. AIM OF THE STUDY: To investigate the role of cardiac biomarkers; cardiac troponin T (cTnT) and N-terminal probrain natriuretic peptide (NT-pro-BNP), and tissue Doppler imaging (TDI), as early predictors of chronic cardiotoxicity in survivors of acute leukemia. PATIENTS AND METHODS: We carried a retrospective study on 50 asymptomatic survivors of acute leukemia who received anthracycline in their treatment protocols. All patients underwent blood sampling to determine the levels of NT-pro-BNP and cTnT along with conventional echocardiography and TDI.
RESULTS: None had abnormal cTnT levels. About 20% had abnormal NT-pro-BNP levels. Diastolic dysfunction of the left ventricle was the most significant in conventional echocardiography. TDI was superior as it detected myocardial affection in 10% more than echo. TDI demonstrated global myocardial damage with significant aberrations in peak myocardial velocities and ratios.
CONCLUSIONS: NT-pro-BNP can be used as a sensitive cardiac biomarker in monitoring of anthracycline-induced cardiotoxicity. Follow up is essential to validate the role of NT-pro-BNP as an early marker for late onset anthracycline-induced cardiotoxicity. Tissue Doppler is marvelous as it could detect early cardiac dysfunction even in those with normal study by conventional echocardiography.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664114     DOI: 10.1179/102453312X13376952196412

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  21 in total

1.  Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.

Authors:  Lu Cao; Gang Cai; Cai Chang; Ai-Yu Miao; Xiao-Li Yu; Zhao-Zhi Yang; Jin-Li Ma; Qian Zhang; Jiong Wu; Xiao-Mao Guo; Jia-Yi Chen
Journal:  Oncologist       Date:  2015-05-01

Review 2.  Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Authors:  Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer
Journal:  Lancet Oncol       Date:  2015-03       Impact factor: 41.316

3.  Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment.

Authors:  Eric J Chow; Kasey J Leger; Neel S Bhatt; Daniel A Mulrooney; Colin J Ross; Sanjeev Aggarwal; Neha Bansal; Matthew J Ehrhardt; Saro H Armenian; Jessica M Scott; Borah Hong
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 4.  Alternative Biomarkers for Combined Biology.

Authors:  Yong-Hyun Kim; Jennifer Kirsop; Wai Hong Wilson Tang
Journal:  Heart Fail Clin       Date:  2017-04       Impact factor: 3.179

Review 5.  Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients.

Authors:  Thomas D Ryan; Rajaram Nagarajan; Justin Godown
Journal:  Curr Treat Options Oncol       Date:  2019-05-25

Review 6.  Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors.

Authors:  Muhammad Asim Shahzad; Rizwan Ishtiaq; Umar Zahid; Faiz Anwer
Journal:  BMJ Case Rep       Date:  2016-11-16

7.  Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort.

Authors:  Carrie A Geisberg; Wissam M Abdallah; Monica da Silva; Cheri Silverstein; Holly M Smith; Vandana Abramson; Ingrid Mayer; Julie Means-Powell; Darla Freehardt; Brenda White; Daniel Lenihan; Douglas B Sawyer
Journal:  J Card Fail       Date:  2013-01       Impact factor: 5.712

Review 8.  Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors:  Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal:  Clin Biochem       Date:  2014-11-07       Impact factor: 3.281

9.  Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients.

Authors:  Krithika Srikanthan; Rebecca Klug; Maria Tirona; Ellen Thompson; Haresh Visweshwar; Nitin Puri; Joseph Shapiro; Komal Sodhi
Journal:  J Clin Exp Cardiolog       Date:  2017-03-22

Review 10.  Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.

Authors:  Lars Michel; Tienush Rassaf; Matthias Totzeck
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.